Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H13N5O3 |
| Molecular Weight | 239.2312 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)C2=C(N1)N(CC[C@@H](O)CO)C=N2
InChI
InChIKey=QOVUZUCXPAZXDZ-RXMQYKEDSA-N
InChI=1S/C9H13N5O3/c10-9-12-7-6(8(17)13-9)11-4-14(7)2-1-5(16)3-15/h4-5,15-16H,1-3H2,(H3,10,12,13,17)/t5-/m1/s1
| Molecular Formula | C9H13N5O3 |
| Molecular Weight | 239.2312 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:14:29 UTC 2023
by
admin
on
Sat Dec 16 16:14:29 UTC 2023
|
| Record UNII |
4G4Z4676IS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
||
|
NCI_THESAURUS |
C1556
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
||
|
NCI_THESAURUS |
C29575
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4G4Z4676IS
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
CHEMBL1744042
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
SUB05943MIG
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
135410214
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
C037591
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
100000085863
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
86304-28-1
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
DTXSID30235484
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
C73198
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY | |||
|
5562
Created by
admin on Sat Dec 16 16:14:30 UTC 2023 , Edited by admin on Sat Dec 16 16:14:30 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
The 9-(3,4-dihydroxybut-1-yl)guanine (bucyclovir, 23) with a hydroxyl directly attached to the butyl side chain is very potent against HSV-1 and HSV-2 (IC50=0.4 μM against HSV-1 and 0.9 μM against HSV-2). The stereochemistry of the 3-position of bucyclovir is crucial in determining the antiherpetic activities. While the R configuration is very potent, the S-isomer (24) is essentially inactive against HSV-1 and HSV-2
IC50
|
||
|
TARGET ORGANISM->INHIBITOR |
The 9-(3,4-dihydroxybut-1-yl)guanine (bucyclovir, 23) with a hydroxyl directly attached to the butyl side chain is very potent against HSV-1 and HSV-2 (IC50=0.4 μM against HSV-1 and 0.9 μM against HSV-2). The stereochemistry of the 3-position of bucyclovir is crucial in determining the antiherpetic activities. While the R configuration is very potent, the S-isomer (24) is essentially inactive against HSV-1 and HSV-2.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
